抗表皮生长因子疫苗抗体增强酪氨酸激酶抑制剂疗效并延缓EGFR突变肺癌细胞耐药出现
本研究在EGFR突变NSCLC细胞系及吉非替尼/奥希替尼耐药细胞中,探讨抗EGF疫苗抗体(anti-EGF VacAbs)联合EGFR-TKIs的作用。结果显示anti-EGF VacAbs抑制EGF诱导的增殖和EGFR下游信号,并显著增强所有测试TKIs的抗肿瘤活性,同时显著延缓体外EGFR-TKI耐药克隆的出现。结论提示EGFR突变患者可从EGF免疫治疗中获益,尤其联合EGFR-TKIs。
要点
- 抗EGF疫苗抗体抑制EGFR突变细胞的EGF诱导增殖及下游信号。
- 抗EGF疫苗抗体显著增强所有测试EGFR-TKIs的抗肿瘤活性。
- 抗EGF疫苗抗体在体外显著延缓EGFR-TKI耐药克隆出现。
核心结论
- EGFR突变患者可从抗EGF免疫治疗中获益,尤其联合EGFR-TKIs时。
研究设计与样本
- 研究使用EGFR突变NSCLC细胞系H1975和PC9,以及来自PC9的吉非替尼和奥希替尼耐药细胞。
- 细胞 treated with anti-EGF VacAbs 和/或 EGFR-TKIs,通过增殖试验、FACS、qRT-PCR和Western blotting分析。
主要发现
- 兔来源anti-EGF VacAbs抑制EGF诱导的细胞增殖和周期进展,并抑制EGFR突变细胞的下游EGFR信号。
- EGF疫苗接种患者血清也能阻断EGFR效应器的激活。
- 联合时,anti-EGF VacAbs显著增强所有测试TKIs的抗肿瘤活性,抑制Erk1/2磷酸化,阻断STAT3激活,下调AXL表达。
- anti-EGF VacAbs在体外显著延缓EGFR-TKI耐药克隆的出现。
临床怎么用
- EGFR突变患者可考虑EGF免疫治疗,尤其与EGFR-TKIs联合。
- 一项EGF疫苗联合阿法替尼的I期试验已启动。
局限性
- 研究为体外细胞系实验,需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mutations in EGFR correlate with impaired response to immune checkpoint inhibitors and the development of novel immunotherapeutic approaches for EGFR mutant NSCLC is of particular interest. Immunization against epidermal growth factor (EGF) has shown efficacy in a phase III trial including unselected NSCLC patients, but little was known about the mechanisms involved in the effects of the anti-EGF antibodies generated by vaccination (anti-EGF VacAbs) or their activity in tumor cells with EGFR mutations. METHODS: The EGFR-mutant, NSCLC cell lines H1975, and PC9, together with several gefitinib and osimertinib-resistant cells derived from PC9, were treated with anti-EGF VacAbs and/or EGFR tyrosine kinase inhibitors (TKIs). Cell viability was analyzed by proliferation assays, cell cycle by fluorescence-activated cell sorting analysis, and levels of RNA and proteins by quantitative retro-transcription polymerase chain reaction and Western blotting. RESULTS: Anti-EGF VacAbs generated in rabbits suppressed EGF-induced cell proliferation and cycle progression and inhibited downstream EGFR signaling in EGFR-mutant cells. Sera from patients immunized with an EGF vaccine were also able to block activation of EGFR effectors. In combination, the anti-EGF VacAbs significantly enhanced the antitumor activity of all TKIs tested, suppressed Erk1/2 phosphorylation, blocked the activation of signal transducer and activator of transcription 3 (STAT3) and downregulated the expression of AXL receptor tyrosine kinase (AXL). Finally, anti-EGF VacAbs significantly delayed the emergence in vitro of EGFR TKI resistant clones. CONCLUSIONS: EGFR-mutant patients can derive benefit from immunization against EGF, particularly if combined with EGFR TKIs. A phase I trial of an EGF vaccine in combination with afatinib has been initiated.
引用
- Codony-Servat J, García-Roman S, Molina-Vila MÁ, et al. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. J Thorac Oncol. 2018. PMID: 29751136. doi:10.1016/j.jtho.2018.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。